Viktravi

deal

Pharma

How one hot protein family is driving cancer drug deals: report

Kinase inhibitors to treat cancer have driven nearly $100 billion in deals since 2010, a trend that's likely to grow, SVB Leerink analysts predict.

Arlene Weintraub Aug 21, 2019 11:55am

EU flag

Key EU panel backs GW's Epidyolex, Bayer's Vitrakvi and more

Jul 26, 2019 10:12am

Bayer

Activist Elliott wields Bayer stake to push 2-way split

Dec 10, 2018 12:12pm